Ash Jayagopal
Equibles does not estimate personal net worth.
About Ash Jayagopal
Opus Genetics, Inc. reported in an 8-K filed February 16, 2024 that Ash Jayagopal was appointed Chief Scientific and Development Officer, effective February 14, 2024. Ash Jayagopal has spoken on 1 investor event across 1 company, most recently for Opus Genetics, Inc. on September 9, 2026. The companies whose calls Ash Jayagopal spoke on are classified in the Healthcare sector.
“Ocuphire Pharma, Inc. (Nasdaq: OCUP) ("Ocuphire"), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today.”
Ash Jayagopal on recent calls
“I'll now walk you through a few individual participant case studies in more detail and then turn it back over to George to close with our next step for the program.”
Affiliation history
-
Opus Genetics, Inc. (IRD)
Proxy statement
Start not stated–2024-04-29
Last confirmed by a filing; no departure on record